Recommendation of the President – Qinlock (ripretinib)

On 25 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 20/2025 on the appraisal Qinlock (ripretinib) in the medical program “Treatment of patients with advanced gastrointestinal stromal tumor (GIST) (ICD-10: C15, C16, C17, C18, C20, C48)”

Publication in Public Information Bulletin (BIP) >>